F11 and Rare hereditary thrombophilia: In summary, the ongoing exploration and validation of thrombophilia biomarkers such as P- and E-selectin, FVIII, FXI, NETs, EVs, and MPs hold immense promise to revolutionize how thrombotic risk is assessed, monitored, and treated.